Invitation to Asia Regulatory Conference 2013: Regulatory Convergence and Cooperation to Improve Access and Quality

Dear Colleague,

We would like to cordially invite you to Asia Regulatory Conference 2013: Regulatory Convergence and Cooperation to Improve Access and Quality at Raffles City Convention Center in Singapore on January 28-30, 2013. This meeting is co-organized, along with DIA, by IFPMA and HSA.

For three days, local and multinational pharmaceutical companies and clinical research professionals within global regulatory and beyond will attend interactive presentations, exciting sessions, and new opportunities to explore better patient solutions. We have attached the link to the program regarding the conference for your review, Asia Regulatory Conference 2013 and ease for you to register for this dynamic conference. 

Thank you in advance for your support and look forward to seeing you in Singapore for this innovative event!

Ling Su, Ph.D.
President, DIA Board of Directors

Be a Part of Asia’s Most Innovative Regulatory Conference!

Be a Part of Asia’s Most Innovative Regulatory Conference!   OVERVIEW Join health authority representatives and industry professionals from Asian and ICH member countries as they continue to discuss regulatory aspects of ICH, APEC and ASEAN convergence initiatives, good regulatory practices, quality and GMP, global drug development, and pharmacovigilance.   OBJECTIVES This three-day conference offers a unique opportunity for key stakeholders from health authorities, local and multinational pharmaceutical companies, and clinical research to meet and exchange views, discuss topics of interest and identify focus areas for ongoing efforts to increase patient access to new and improved medicines.   This conference will provide a forum to: • Facilitate discussion on common issues in the regulatory and technical areas in Asia • Encourage greater convergence of regulatory requirements in Asia • Strengthen cooperation between Asian regulatory authorities and pharmaceutical industry Day One – Research and Development Day Two – Good Regulatory Practices Day Three – 21st century Global Regulatory Challenges   Register Online     Program Overview     View PDF Program committee chairs Arun Mishra Director Global Regulatory Affairs GlaxoSmithKline, UK John C.W. Lim Chief Executive Officer Health Sciences Authority, Singapore  Who Should Attend Are you a Representative of Health Authorities, a Regulatory Affairs professional, or a professional involved in or interested in the aspects surrounding registration of medicinal products and regulatory convergence initiatives in Asia? If so, then this conference is for you. Ministries of Health and Medicines Regulatory Authorities Regulatory Affairs Clinical Research and Development Safety and Pharmacovigilance Clinical Trial and Project Management CMC/Quality (Quality, Manufacturing and Controls)   Register Online     Program Overview     View PDF To know more contact Ellen.Diegel@diahome.org.

IFPMA - Policies that Encourage Innovation in Middle-income Countries - report by Charles River Assoc

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked Charles River Associates (CRA) to investigate the conditions necessary to encourage innovation in middle-income countries. Ultimately, the purpose of this project is to evaluate the policies of host governments that encourage investment in innovative activities and the implications for future innovation policy.

The report focuses on eight case study countries (Brazil, China, Colombia, India, Malaysia, Russia, South Africa and South Korea). The case studies were chosen using a number of criteria. Firstly, we selected countries from different geographic regions, focusing on those that had been most successful in developing innovative activities to date in their region. Secondly, we chose countries that illustrate a range of different policy approaches. Thirdly, we chose a mix of countries with a long-standing objective of developing an innovative industry as well as countries that had only relatively recently embarked on this. Finally, we included South Korea as a basis of comparison, which was a middleincome country when it instigated its programme to encourage pharmaceutical innovation and provides a longer term perspective on what is achievable.

In addition, to reviewing the existing academic literature and government sources, we undertook 25 interviews with government officials, academics, industry trade associations and individual companies.

 

Developing World Health Partnerships Directory

Developing World Health Partnerships Directory reflects pharmaceutical industry’s and partners’ commitment to improving health in developing countries

 

Developing World Health Parntnerships Directory

Directory highlights commitment of the research-based pharmaceutical industry and partners to improve health in the developing world through 220 partnerships operating in more than 160 countries

 

The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) published the 2012 update to its Developing World Health Partnerships Directory today. Now totaling 220 and reaching people in more than 160 countries, these health partnerships highlight the commitment of research-based pharmaceutical industry and its many partners including governments, intergovernmental organizations, nongovernmental organizations, private sector companies and universities to improve health around the world.

The launch of this directory coincides with the release of an independent review of the contributions these health partnerships' make to the health of people in low- and middle-income countries.

 

for complete article click below:

http://globalhealthprogress.org/developing-world-health-partnerships-directory-reflects-pharmaceutical-industry%E2%80%99s-and-partners%E2%80%99

Regulatory Convergence and Cooperation to Improve Access and Quality - AsiaReg2013

Regulatory Conference Registration Now Available! To kick off 2013, the Asia Regulatory Conference is bringing together global regulatory professionals to share past experiences and new practices. Don’t miss this exciting event to interact with regulatory and other professionals! OVERVIEW Join health authority representatives and industry professionals from Asian and ICH member countries as they continue to discuss regulatory aspects of ICH, APEC and ASEAN convergence initiatives, good regulatory practices, quality and GMP, global drug development, and pharmacovigilance. OBJECTIVES This three-day conference offers a unique opportunity for key stakeholders from health authorities, local and multinational pharmaceutical companies, and clinical research to meet and exchange views, discuss topics of interest and identify focus areas for ongoing efforts to increase patient access to new and improved medicines. This conference will provide a forum to: • Facilitate discussion on common issues in the regulatory and technical areas in Asia • Encourage greater convergence of regulatory requirements in Asia • Strengthen cooperation between Asian regulatory authorities and pharmaceutical industry Day One – Research and Development Day Two – Good Regulatory Practices Day Three – 21st century Global Regulatory Challenges   Register Online     Program Overview Program committee chairs Arun Mishra Director Global Regulatory Affairs GlaxoSmithKline, UK John C.W. Lim Chief Executive Officer Health Sciences Authority, Singapore  Who Should Attend Representatives of Health Authorities, Regulatory Affairs professionals, and other professionals involved in or interested in the aspects surrounding registration of medicinal products and regulatory convergence initiatives in Asia. Ministries of Health and Medicines Regulatory Authorities Regulatory Affairs Clinical Research and Development Safety and Pharmacovigilance Clinical Trial and Project Management CMC/Quality (Quality, Manufacturing and Controls)   Register Online      Read More To know more contact Ellen.Diegel@diahome.org.